Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2001

01-12-2002 | Paper Report

OSM-induced periosteal bone apposition

Author: Riako Masuda

Published in: Arthritis Research & Therapy | Issue 1/2001

Login to get access

Excerpt

Oncostatin M (OSM) is a member of the interleukin (IL)-6 family and induces the expression of IL-6. Since the level of OSM is elevated in the synovial fluid, but not in the serum, in RA, OSM is considered to play a role in the local inflammation seen in RA. To elucidate the influence of OSM on joint inflammation, the authors induced inflammation in wild-type and IL-6 deficient mice using an injection of adenoviral vector expressing murine OSM (AdmuOSM). …
Literature
1.
de Hooge ASK, van de Loo FAJ, Bennink MB, de Jong DS, Arntz OJ, Lubberts E, Richards CD, van den Berg WB: Adenoviral transfer of murine Oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-κB ligand. Am J Pathol . 2002, 160: 1733-1743.PubMedPubMedCentralCrossRef
Metadata
Title
OSM-induced periosteal bone apposition
Author
Riako Masuda
Publication date
01-12-2002
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2001
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar-2002-77300

Other articles of this Issue 1/2001

Arthritis Research & Therapy 1/2001 Go to the issue

Paper Report

GILT influences antigen processing

Paper Report

Modulation of angiogenesis by VEGF and placental growth factor

Paper Report

TNFR2 activates JNK but not MAPK pathways

Paper Report

An interferon-inducible gene in lupus susceptibility

Commentary

From immunoglobulin gene fingerprinting to motif-specific hybridization: advances in the analysis of B lymphoid clonality in rheumatic diseases

Paper Report

SS-56: a novel auto-antigen
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits